Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A42692 | 33746456 | J Clin Exp Hepatol | Changing Nomenclature from Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Fatty Liver Disease - Not Only Premature But Also Confusing. | 2020 | Details |
| A42693 | 33746439 | J Clin Exp Hepatol | Nonalcoholic Fatty Liver Disease: Lessons Learnt in the Last Five Years. | 2020 | Details |
| A42694 | 33742991 | J Chin Med Assoc | Is there any useful surrogate to evaluate metabolic fatty liver disease? | 2021 | Details |
| A42695 | 33739258 | J Clin Sleep Med | The association of obstructive sleep apnea with dyslipidemia in Korean children and adolescents: a single-center, cross-sectional study. | 2021 | Details |
| A42696 | 33739235 | Crit Rev Clin Lab Sci | Potential value and impact of data mining and machine learning in clinical diagnostics. | 2021 | Details |
| A42697 | 33739132 | AJR Am J Roentgenol | Quantification of Liver Steatosis: Is CT Equivalent to PDFF? | 2021 | Details |
| A42698 | 33728291 | Can J Gastroenterol Hepatol | Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models. | 2021 | Details |
| A42699 | 33724502 | Hepatology | Exosomes and MicroRNA-223 at the Intersection of Inflammation and Fibrosis in NAFLD. | 2021 | Details |
| A42700 | 33724489 | Hepatology | Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis. | 2021 | Details |
| A42701 | 33722548 | J Am Acad Dermatol | Psoriasis in liver disease: Associations beyond nonalcoholic fatty liver disease. | 2021 | Details |
| A42702 | 33720361 | Toxicol Sci | Genetics-Based Approach to Identify Novel Genes Regulated by the Aryl Hydrocarbon Receptor in Mouse Liver. | 2021 | Details |
| A42703 | 33717101 | Front Immunol | Natural Killer Cells: Friend or Foe in Metabolic Diseases? | 2021 | Details |
| A42704 | 33712438 | Gut | NAFLD in lean individuals: not a benign disease. | 2021 | Details |
| A42705 | 33709605 | J Gastroenterol Hepatol | Artificial intelligence in liver disease. | 2021 | Details |
| A42706 | 33693864 | J Nutr | Milk Fat Globule Membrane Supplementation During Suckling Ameliorates Maternal High Fat Diet-Induced Hepatic Steatosis in Adult Male Offspring of Mice. | 2021 | Details |
| A42707 | 33693456 | Am J Clin Pathol | The Utility of Liver Biopsy in the Evaluation of Liver Disease and Abnormal Liver Function Tests. | 2021 | Details |
| A42708 | 33682953 | Nutr Clin Pract | Endogenous Glucose Production in Critical Illness. | 2021 | Details |
| A42709 | 33682344 | FEBS J | Metabolic roles of G protein-coupled receptor signaling in obesity and type 2 diabetes. | 2021 | Details |
| A42710 | 33681679 | Hepatol Commun | Fatty Acid Desaturase 1 Influences Hepatic Lipid Homeostasis by Modulating the PPARα-FGF21 Axis. | 2020 | Details |
| A42711 | 33676949 | J Hepatol | Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease". | 2021 | Details |
| A42712 | 33674915 | J Gen Intern Med | Prevalence of Nonalcoholic Fatty Liver Disease and Hepatic Fibrosis Among US Adults with Prediabetes and Diabetes, NHANES 2017-2018. | 2021 | Details |
| A42713 | 33666565 | J Mol Endocrinol | Oleanolic acid derivative HA-20 inhibits adipogenesis in a manner involving PPARγ-FABP4/aP2 pathway. | 2021 | Details |
| A42714 | 33666272 | Hepatology | Macrophage Heterogeneity in NASH: More Than Just Nomenclature. | 2021 | Details |
| A42715 | 33660954 | Croat Med J | Nonalcoholic fatty liver disease - a growing public health problem. | 2021 | Details |
| A42716 | 33659163 | J Med Ultrasound | Ultrasonographic Features Associated with Diffuse Hepatosteatosis among Diabetic Obese and Normal Body Mass Index Patients. | 2020 | Details |
| A42717 | 33654016 | Curr Opin Gastroenterol | Statins for treatment of chronic liver disease. | 2021 | Details |
| A42718 | 33653988 | Eur J Gastroenterol Hepatol | The liver in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. | 2021 | Details |
| A42719 | 33653592 | J Hepatol | Clinical utility of polygenic risk scores for predicting NAFLD disorders. | 2021 | Details |
| A42721 | 33649876 | Inflammation | Neutrophil-Induced Liver Injury and Interactions Between Neutrophils and Liver Sinusoidal Endothelial Cells. | 2021 | Details |
| A42722 | 33649583 | Nat Rev Gastroenterol Hepatol | What are the clinical settings and outcomes of lean NAFLD? | 2021 | Details |
| A42723 | 33642147 | J Diabetes Complications | Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient. | 2021 | Details |
| A42724 | 33640436 | Gastroenterology | Induced Pluripotent Stem Cell-derived Hepatocytes From Patients With Nonalcoholic Fatty Liver Disease Display a Disease-specific Gene Expression Profile. | 2021 | Details |
| A42725 | 33638172 | Hepatology | Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans. | 2021 | Details |
| A42726 | 33638026 | Mol Cell Biochem | Endoplasmic reticulum stress and autophagy are involved in adipocyte-induced fibrosis in hepatic stellate cells. | 2021 | Details |
| A42727 | 33630308 | Hepatology | Long Noncoding RNA H19: A Key Player in Liver Diseases. | 2021 | Details |
| A42728 | 33626411 | Ann Hepatol | Non-invasive diagnosis of non-alcoholic fatty liver disease using an algorithm combining clinical indexes and ultrasonographic measures. | 2021 | Details |
| A42729 | 33618858 | Clin Ther | Nonalcoholic Fatty Liver Disease: Epidemiology, Assessments, and Interventions Entering 2021. | 2021 | Details |
| A42730 | 33617924 | J Hepatol | Dynamics of liver stiffness in chronic hepatitis B patients with concurrent metabolic-associated fatty liver disease. | 2021 | Details |
| A42731 | 33616986 | Aliment Pharmacol Ther | Editorial: microRNAs for the diagnosis of fatty liver disease in the population-are we inching closer towards the target? Authors' reply. | 2021 | Details |
| A42732 | 33612688 | Intern Med | Potential Effect of a Selective Peroxisome Proliferator-activated Receptor Alpha Modulator on Metabolic Dysfunction-associated Fatty Liver Disease. | 2021 | Details |
| A42733 | 33610759 | Clin Gastroenterol Hepatol | MAFLD and Cardiovascular Events: What Does the Evidence Show? | 2021 | Details |
| A42734 | 33608424 | Diabetes | Regulation of Hepatic Metabolism and Cell Growth by the ATF/CREB Family of Transcription Factors. | 2021 | Details |
| A42735 | 33604316 | Can J Gastroenterol Hepatol | A New CYP2E1 Inhibitor, 12-Imidazolyl-1-dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma. | 2021 | Details |
| A42736 | 33604315 | J Hepatocell Carcinoma | Mechanisms Underlying Hepatocellular Carcinoma Progression in Patients with Type 2 Diabetes. | 2021 | Details |
| A42737 | 33603515 | Risk Manag Healthc Policy | MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease. | 2021 | Details |
| A42738 | 33600093 | Eur J Gastroenterol Hepatol | Pancreatic and hepatobiliary manifestations of nonalcoholic fatty pancreatic disease: a referral multi-center experience. | 2021 | Details |
| A42739 | 33599378 | Liver Transpl | Prevalence and Impact of Fatty Liver Disease in Adult Deceased Liver Transplant Donors: Metabolic-Associated Fatty Liver Disease or Nonalcoholic Fatty Liver Disease? | 2021 | Details |
| A42740 | 33599321 | Aliment Pharmacol Ther | Editorial: metagenome-assembled genomes in non-alcoholic fatty liver disease. | 2021 | Details |
| A42741 | 33599279 | Nephrol Dial Transplant | Incidence and predictors of non-alcoholic fatty liver disease among patients with chronic kidney disease. | 2021 | Details |
| A42742 | 33596631 | J Biol Regul Homeost Agents | Vitamin D3 supplementation in controlling metabolic changes associated with non-alcoholic steatohepatitis. | 2021 | Details |
| A42743 | 33595808 | Hepatol Int | Author's reply to "Thromboelastometry in patients with advanced chronic liver disease: a complex interplay". | 2021 | Details |
| A42744 | 33595181 | Liver Int | Liver chemistries in glycogenic hepatopathy associated with type 1 diabetes mellitus: A systematic review and pooled analysis. | 2021 | Details |
| A42745 | 33595107 | J Physiol | Sex-specific metabolic changes induced by high fructose corn syrup during adolescence: novel evidence from metabolomic and microbiome analyses in mice. | 2021 | Details |
| A42746 | 33589573 | Aging (Albany NY) | Glutamine, fatty liver disease and aging. | 2021 | Details |
| A42747 | 33587953 | J Hepatol | MAFLD: Now is the time to capitalize on the momentum. | 2021 | Details |
| A42748 | 33586679 | J Clin Invest | Muscle Krüppel-like factor 15 regulates lipid flux and systemic metabolic homeostasis. | 2021 | Details |
| A42749 | 33586126 | Am J Clin Dermatol | Psoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges. | 2021 | Details |
| A42750 | 33584986 | World J Hepatol | Autophagy in liver diseases. | 2021 | Details |
| A42751 | 33582129 | J Hepatol | Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. | 2021 | Details |
| A42752 | 33581757 | Lancet Gastroenterol Hepatol | Endorsing the redefinition of fatty liver disease. | 2021 | Details |
| A42753 | 33581358 | Clin Gastroenterol Hepatol | Impact of the New Metabolic-Associated Fatty Liver Disease (MAFLD) on NAFLD Patients Classification in Italy. | 2021 | Details |
| A42754 | 33576084 | Adv Mater | In Vivo Three-Photon Imaging of Lipids using Ultrabright Fluorogens with Aggregation-Induced Emission. | 2021 | Details |
| A42755 | 33568795 | Nat Rev Gastroenterol Hepatol | The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. | 2021 | Details |
| A42756 | 33566680 | AJR Am J Roentgenol | Editorial Comment: Liver Fat Quantification by Ultrasound-Potential to Change Diagnosis and Management of Pediatric NAFLD. | 2021 | Details |
| A42757 | 33565156 | J Magn Reson Imaging | Editorial for "Automated Analysis of Multiparametric MRI/MRE Exams for Prediction of NASH". | 2021 | Details |
| A42758 | 33561215 | J Nutr | Associations of Serum Fatty Acid Proportions with Obesity, Insulin Resistance, Blood Pressure, and Fatty Liver: The Cardiovascular Risk in Young Finns Study. | 2021 | Details |
| A42759 | 33552482 | Clin Liver Dis (Hoboken) | Nonalcoholic Fatty Liver Disease and Recent Guideline Updates. | 2021 | Details |
| A42760 | 33552481 | Clin Liver Dis (Hoboken) | Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. | 2021 | Details |
| A42761 | 33546550 | J Coll Physicians Surg Pak | Association of Gender Difference to Platelet Count (PC), Mean Platelet Volume (MPV) and Platelet Distribution Width (PDW) Levels in Non-alcoholic Fatty Liver Disease (NAFLD) Patients. | 2021 | Details |
| A42762 | 33545738 | Hepatology | Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box. | 2021 | Details |
| A42763 | 33545720 | Planta Med | Bioaccessibility and Absorption of Flavonoid C-glycosides from Abrus mollis Using Simulated Digestion, Caco-2 Cell, and In Situ Single-pass Perfusion Models. | 2021 | Details |
| A42764 | 33544416 | Hepatology | Emerging Metabolic and Transcriptomic Signature of PNPLA3-Associated NASH. | 2021 | Details |
| A42765 | 33535939 | Exp Clin Transplant | Liver Transplantation in Alstrom Syndrome: A Case Report. | 2021 | Details |
| A42766 | 33535476 | Foods | Protection of Fatty Liver by the Intake of Fermented Soybean Paste, Miso, and Its Pre-Fermented Mixture. | 2021 | Details |
| A42767 | 33529671 | J Hepatol | Reply to: "NNMT aggravates hepatic steatosis but alleviates liver injury in alcoholic liver disease" and "Two sides of NNMT in alcoholic and non-alcoholic fatty liver development". | 2021 | Details |
| A42768 | 33527946 | Food Funct | Uridine attenuates obesity, ameliorates hepatic lipid accumulation and modifies the gut microbiota composition in mice fed with a high-fat diet. | 2021 | Details |
| A42769 | 33526291 | J Hepatol | Erratum to: "MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcoholic-associated fatty liver and steatohepatitis (J Hepatol 2020; 73: 616-627)". | 2021 | Details |
| A42770 | 33525643 | Nutrients | The Marine Microalga, Tisochrysis lutea, Protects against Metabolic Disorders Associated with Metabolic Syndrome and Obesity. | 2021 | Details |
| A42771 | 33523348 | Hepatol Int | Targeting the ileal bile salt transporter in the treatment of non-alcoholic fatty liver disease. | 2021 | Details |
| A42772 | 33522247 | J Am Heart Assoc | Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1. | 2021 | Details |
| A42773 | 33515802 | Ann Hepatol | Reply to: Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. | 2021 | Details |
| A42774 | 33511289 | Med One | Artificial Intelligence Pipeline to Bridge the Gap between Bench Researchers and Clinical Researchers in Precision Medicine. | 2020 | Details |
| A42775 | 33509738 | Dig Liver Dis | Reply to: "Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?" | 2021 | Details |
| A42776 | 33508742 | Redox Biol | Long non-coding RNA Meg3 deficiency impairs glucose homeostasis and insulin signaling by inducing cellular senescence of hepatic endothelium in obesity. | 2021 | Details |
| A42777 | 33505493 | Evid Based Complement Alternat Med | Use of Network Pharmacology to Investigate the Mechanism by Which Allicin Ameliorates Lipid Metabolism Disorder in HepG2 Cells. | 2021 | Details |
| A42778 | 33500723 | Theranostics | Activation of N-methyl-D-aspartate receptor regulates insulin sensitivity and lipid metabolism. | 2021 | Details |
| A42779 | 33497764 | J Hepatol | Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback. | 2021 | Details |
| A42780 | 33497712 | Metabolism | Role of the gut microbiota in type 2 diabetes and related diseases. | 2021 | Details |
| A42781 | 33493527 | J Hepatol | NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change. | 2021 | Details |
| A42782 | 33489993 | Can J Gastroenterol Hepatol | Diet and Lifestyle in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A42783 | 33485968 | J Hepatol | Hypertension in NAFLD: An uncontrolled burden. | 2021 | Details |
| A42784 | 33485519 | Am J Kidney Dis | Clinical Approach to a Patient With an Acid-Base Disturbance. | 2021 | Details |
| A42785 | 33484771 | J Hepatol | The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD. | 2021 | Details |
| A42786 | 33483258 | Dig Liver Dis | Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk? | 2021 | Details |
| A42787 | 33479538 | Nat Rev Endocrinol | Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. | 2021 | Details |
| A42788 | 33476746 | J Hepatol | Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease. | 2021 | Details |
| A42789 | 33471689 | Endocr Pract | Role of Androgen in Liver Fat Content in Women: Metabolically Advantageous or Disadvantageous? | 2020 | Details |
| A42790 | 33471489 | J Clin Gastroenterol | Replacing the Name of NAFLD With a Metabolic or Another Forename as Indicator of the Era of Stagnation in NASH Studies. | 2021 | Details |
| A42791 | 33460568 | Lancet Gastroenterol Hepatol | CAP for the detection of hepatic steatosis in clinical practice. | 2021 | Details |
| A42792 | 33453398 | Clin Gastroenterol Hepatol | On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. | 2021 | Details |